Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Share Value rises 3%

Sun Pharmaceutical Industries Share Value rises 3% in intraday trade:

To begin with, the share value of Sun Pharmaceutical Industries raised by 3% in intraday trade. Due to the Morgan Stanley supported the overweight stance on Sun Pharma, with the target value of Rs 530 per eq share.

On 12th Feb, the Sun Pharma Advanced Research Company received a CRL for its NDA Taclains. The company will attend a meeting with the US Food and Drug Administration next month. Moreover, the SPARC wants to reproduce its dossier in the next month. 

The volume of sun pharma shares raised by 1.88x and listing with the volumes of 654,539 eq shares. Against, the shares increased 54.81% or 422,811 units. The company also introduced a type 2 diabetes medicine Riomet ER into the US market on Feb 26.

Only, the Riomet ER was the FDA licensed liquid formulation of extended-release metformin. Moreover, the USFDA approved this medicine on 29th August 2019. On 2nd March, the company announced, there was a shortage in generic Version due to the lack of ingredients. Generally, the API supplied from China, due to the virus affected the API drug unavailable.

Sun Pharma shares trading with a gain of 26.50 points reached 369.00 INR with 7.17% up. Its previous close at 369.50 INR on the National Stock Exchange. Sun Pharma shares outstanding with 2,399,300,000.

Related posts

Lupin Ltd June 19th Shares Hiked

nagalavanya

RBI rose WMA limit to Rs 2 lakh crore

Stock Investor

Cadila Healthcare Q4 results: Profit decreased by 15% to Rs 392 crores

Tarun